
VVUSQ
Healthcare · Biotechnology · $2.1M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2020
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 6, 2020 | Time not confirmed | -0.80 | -0.49 | +38.8% |
| Mar 3, 2020 | Time not confirmed | -0.68 | -0.61 | +10.3% |
| Nov 5, 2019 | Time not confirmed | -0.74 | -1.04 | -40.5% |
| Aug 6, 2019 | Time not confirmed | -0.99 | -0.56 | +43.4% |
| Apr 30, 2019 | Time not confirmed | -1.17 | -0.75 | +35.9% |
| Feb 26, 2019 | Time not confirmed | -0.53 | -0.42 | +20.8% |
| Nov 1, 2018 | Time not confirmed | -1.11 | -0.87 | +21.6% |
| Aug 7, 2018 | Time not confirmed | -1.10 | -1.20 | -9.1% |
| May 8, 2018 | Time not confirmed | -1.10 | -1.00 | +9.1% |
| Mar 13, 2018 | Time not confirmed | -1.30 | -1.00 | +23.1% |
VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at…